Lenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature
| Autor: | Flora Cesario, Marco Merlano, Giorgio Borretta, Adele Latina, Nerina Denaro, Lauro Corrado, Fabio Bramardi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Carcinoma Hepatocellular Antineoplastic Agents Disease-Free Survival Iodine Radioisotopes 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Refractory Weight loss Renal cell carcinoma Internal medicine medicine Humans Everolimus Thyroid Neoplasms 030212 general & internal medicine Adverse effect Carcinoma Renal Cell Protein Kinase Inhibitors Thyroid cancer business.industry Phenylurea Compounds Liver Neoplasms General Medicine medicine.disease Combined Modality Therapy Treatment Outcome chemistry 030220 oncology & carcinogenesis Hepatocellular carcinoma Disease Progression Quinolines Female medicine.symptom Lenvatinib business medicine.drug |
| Zdroj: | Oncology. 97:206-210 |
| ISSN: | 1423-0232 0030-2414 |
| Popis: | Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focusing on the role of the immediate multidisciplinary approach to manage AEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|